Immune Effects

Preclinical immune-oncology relevance of apigenin, including PD-L1 modulation, NK-cell effects, and inflammatory signalling.

Evidence level

Most apigenin immune data are mechanistic or animal-supported. There is currently no human evidence for apigenin-specific immune-oncology effects.

NK-cell effects

In vitro studies show that apigenin can promote NK-92 cell proliferation in a dose-dependent manner. In direct flavonoid comparisons, though, apigenin did not significantly stimulate IL-2 or IFN-γ secretion from NK cells, unlike luteolin and quercetin.

That suggests apigenin’s NK-cell relevance is more indirect. The signal appears to run through suppression of immunosuppressive cytokines rather than direct NK-cell activation.

A separate in vitro study found improved NK-cell killing against pancreatic cancer cells after apigenin exposure. That supports further investigation, but not a firm conclusion.

PD-L1 modulation

Apigenin suppresses PD-L1 expression in melanoma cells and in host dendritic cells in animal models. PD-L1 is the checkpoint protein tumours use to suppress T-cell attack.

By lowering PD-L1, apigenin may restore immune recognition of tumour cells in at least some settings. This was shown in mouse melanoma models, where reduced lung metastasis correlated with suppressed STAT3 signalling and lower PD-L1 expression.

This remains animal-supported. Whether apigenin can augment checkpoint inhibitor therapy in humans has not been tested.

Macrophage and inflammatory microenvironment

By suppressing NF-κB and COX-2, apigenin reduces production of pro-inflammatory cytokines including IL-1β, IL-6, TNF-α, and CXCL8.

That may shift the inflammatory milieu away from a pro-tumourigenic state, although direct evidence for macrophage polarisation inside established solid tumours remains limited. For the broader macrophage context, see Macrophages in Cancer.

Apigenin also suppresses the SASP, the inflammatory secretome of senescent stromal cells. That is one of its clearest microenvironmental signals and is covered in more detail in Terrain Support — SASP Suppression, alongside the broader framework in Senescence — The Second Escape Route.

CD8 T-cell relevance

There is no direct evidence that apigenin expands CD8+ cytotoxic T-cell populations in cancer settings.

The PD-L1 data imply reduced T-cell suppression, which could support existing CD8+ activity. At present, that remains inference rather than demonstrated outcome.

Summary

Apigenin has a plausible immune-oncology rationale centred on PD-L1 suppression and SASP reduction. The evidence is mechanistic and animal-supported. No human immune-oncology trials exist.

Its role is best framed as terrain-supportive and potentially complementary to immune-based therapies, not as a standalone immunotherapy.